Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Tenax Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 19.55.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Tenax Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.
The historical rank and industry rank for Tenax Therapeutics's Cash-to-Debt or its related term are showing as below:
TENX'
s Cash-to-Debt Range Over the Past 10 Years
Min: 2.63 Med: 99.83 Max: No Debt
Current: 19.55
During the past 13 years, Tenax Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 2.63. And the median was 99.83.
Tenax Therapeutics Cash-to-Debt Historical Data
The historical data trend for Tenax Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
|
Tenax Therapeutics Annual Data
|
|
Trend |
Apr14 |
Apr15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Cash-to-Debt |
|
|
|
|
|
|
31.58 |
22.01 |
19.19 |
2.63 |
19.55 |
|
Tenax Therapeutics Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Cash-to-Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2.63 |
28.05 |
38.71 |
64.03 |
19.55 |
Competitive Comparison
For the Biotechnology subindustry, Tenax Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tenax Therapeutics Cash-to-Debt Distribution
For the Biotechnology industry and Healthcare sector, Tenax Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Tenax Therapeutics's Cash-to-Debt falls into.
Tenax Therapeutics Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Tenax Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
Tenax Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tenax Therapeutics (Tenax Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction.
Executives
| Robyn Hunter |
director |
95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453 |
| Eliot M Lurier |
officer: Interim CFO |
C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560 |
| Chrisopher Thomas Giordano |
director, officer: CEO |
C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560 |
| Armistice Capital, Llc |
director |
510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
| Armistice Capital Master Fund Ltd. |
director |
C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
| Steven Boyd |
director |
510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
| June Sherie Almenoff |
director |
C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019 |
| Michael H. Davidson |
director |
OMTHERA PHARMACEUTICALS, INC., 707 STATE ROAD, PRINCETON NJ 08540 |
| Declan Doogan |
director |
C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510 |
| Stuart Rich |
officer: Chief Medical Officer |
C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560 |
| Illya Keith Maher |
director |
C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022 |
| Ronald R Blanck |
director |
2001 WALNUT HILL LANE, IRVING TX 75038 |
| Gerald T Proehl |
director |
|
| James P. Mitchum |
director |
C/O NEPHROGENEX, INC., 79 T.W. ALEXANDER DRIVE, RESEARCH TRIANGLE PARK NC 27709 |
| John P Kelley |
officer: Chief Executive Officer |
C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Tenax Therapeutics (Tenax Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TENX has been successfully added to your